一种新的仿生和氧化还原反应的混合脂质聚合物纳米粒子,用于向败血症微环境和调节炎症
Abdelrahman Tageldin1, Mohammed A Gafar2, Eman A Ismail3
1Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Private Bag X54001 Durban, South Africa.
International journal of pharmaceutics
|February 18, 2026
概括
这项研究提出了一种用于细菌性败血症治疗的新型纳米载体. 生物模拟混合脂质聚合物纳米载体准ADAM10,清除毒素,并释放万科米辛作为对败血症环境的反应,改善结果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 细菌性败血症是一种危及生命的疾病,死亡率高.
- 目前的疗法在有效向感染和炎症方面面临挑战.
- 失调的免疫反应和特定的分子点,如ADAM10,是败血症发病的关键.
研究的目的:
- 开发一种可氧化还原反应的生物仿真混合纳米载体 (SC-HLPN) 用于向性败血症治疗.
- 加入一种新型的酸-胺-酸 (S-ss-CG) 结合物,用于双重向和药物释放.
- 评估SC-HLPN在输送万科米辛 (VCM) 和调节炎症通路方面的疗效.
主要方法:
- 合成和S-ss-CG结合物和SC-HLPN的表征.
- 在 silico 和 in vitro 验证了与ADAM10 和α-hemolysin (A-H) 的结合相互作用.
- 评估物理化学性质,药物释放动力学,抗菌活性,抗氧化剂和抗炎作用.
- 在小鼠MRSA败血症模型中的体内评估.
主要成果:
- 在SC-HLPN的研究中,SC-HLPN对ADAM10和AH的特定结合得到了证明.
- 反氧反应性二硫化物键裂变使得在败血症条件下加速VCM释放.
- SC-HLPN在体外表现出增强的抗菌,抗氧化和抗炎性质.
- 在体内研究证实了显著的细菌清除,减少了促炎性细胞因子 (IL-1β,IL-18,IL-6) 和减轻了器官损伤.
结论:
- 开发的SC-HLPN是一个有前途的多功能平台,用于针对性地提供抗生素.
- 该S-ss-CG结合物促进向治疗和控制药物释放在败血症微环境中.
- 通过结合抗菌,抗氧化和抗炎作用,SC-HLPN提供了一种改善败血症治疗结果的潜在策略.
相关概念视频
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
26
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
26
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
31
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
31
01:24Modified-Release Drug Delivery Systems: Site-Targeted
29
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
29